Baseline characteristics for all patients and for the donor subgroups at the time of study initiation
| . | Control . | Intervention . | ||||
|---|---|---|---|---|---|---|
| All (n = 73) . | VUD (n = 45) . | MSD (n = 28) . | All (n = 72) . | VUD (n = 50) . | MSD (n = 22) . | |
| Males, n (%) | 43 (59) | 22 (49) | 21 (75) | 38 (53) | 25 (50) | 13 (59) |
| Age, mean (SD), y | 49 (12) | 51 (12) | 45 (12) | 49 (14) | 49 (15) | 49 (10) |
| Disease | ||||||
| AML | 39 (54) | 23 (51) | 16 (58) | 44 (61) | 32 (64) | 12 (55) |
| ALL | 19 (26) | 12 (27) | 7 (25) | 10 (14) | 7 (14) | 3 (14) |
| MDS | 14 (19) | 10 (22) | 4 (14) | 13 (18) | 8 (16) | 5 (23) |
| CMML | 1 (1) | 0 (0) | 1 (4) | 5 (7) | 3 (6) | 2 (9) |
| Disease status | ||||||
| CR1 | 64 (88) | 37 (82) | 27 (96) | 63 (88) | 45 (90) | 18 (82) |
| >CR1 | 4 (5.5) | 4 (9) | 0 (0) | 7 (10) | 3 (6) | 4 (18) |
| Untreated MDS | 1 (1) | 1 (2) | 0 (0) | 1 (1) | 1 (2) | 0 (0) |
| Unknown | 4 (5.5) | 3 (7) | 1 (4) | 1 (1) | 1 (2) | 0 (0) |
| MAC | 33 (45) | 18 (40) | 15 (54) | 31 (43) | 21 (42) | 10 (45) |
| Cyclophosphamide/TBI | 24 (33) | 13 (29) | 11 (39) | 22 (31) | 17 (34) | 5 (23) |
| Busulfan/cyclophosphamide | 9 (12) | 5 (11) | 4 (14) | 9 (13) | 4 (8) | 5 (23) |
| RIC | 40 (55) | 27 (60) | 13 (46) | 41 (57) | 29 (58) | 12 (55) |
| Fludarabine/melphalan | 40 (55) | 27 (60) | 13 (46) | 41 (57) | 29 (58) | 12 (55) |
| CMV status | ||||||
| D+R+ | 30 (41) | 14 (31) | 16 (57) | 25 (35) | 10 (20) | 15 (68) |
| D+R− | 10 (14) | 8 (18) | 2 (7) | 12 (17) | 9 (18) | 3 (14) |
| D−R+ | 19 (26) | 15 (33) | 4 (14) | 18 (25) | 15 (30) | 3 (14) |
| D−R− | 14 (19) | 8 (18) | 6 (21) | 17 (24) | 16 (32) | 1 (5) |
| ABO disparity | ||||||
| Matched | 50 (68) | 26 (58) | 24 (86) | 38 (53) | 23 (46) | 15 (68) |
| Minor mismatch | 10 (14) | 8 (18) | 2 (7) | 16 (22) | 14 (28) | 2 (9) |
| Major mismatch | 11 (15) | 10 (22) | 1 (4) | 11 (15) | 10 (20) | 1 (5) |
| Major and minor mismatch | 2 (3) | 1 (2) | 1 (4) | 7 (10) | 3 (6) | 4 (18) |
| . | Control . | Intervention . | ||||
|---|---|---|---|---|---|---|
| All (n = 73) . | VUD (n = 45) . | MSD (n = 28) . | All (n = 72) . | VUD (n = 50) . | MSD (n = 22) . | |
| Males, n (%) | 43 (59) | 22 (49) | 21 (75) | 38 (53) | 25 (50) | 13 (59) |
| Age, mean (SD), y | 49 (12) | 51 (12) | 45 (12) | 49 (14) | 49 (15) | 49 (10) |
| Disease | ||||||
| AML | 39 (54) | 23 (51) | 16 (58) | 44 (61) | 32 (64) | 12 (55) |
| ALL | 19 (26) | 12 (27) | 7 (25) | 10 (14) | 7 (14) | 3 (14) |
| MDS | 14 (19) | 10 (22) | 4 (14) | 13 (18) | 8 (16) | 5 (23) |
| CMML | 1 (1) | 0 (0) | 1 (4) | 5 (7) | 3 (6) | 2 (9) |
| Disease status | ||||||
| CR1 | 64 (88) | 37 (82) | 27 (96) | 63 (88) | 45 (90) | 18 (82) |
| >CR1 | 4 (5.5) | 4 (9) | 0 (0) | 7 (10) | 3 (6) | 4 (18) |
| Untreated MDS | 1 (1) | 1 (2) | 0 (0) | 1 (1) | 1 (2) | 0 (0) |
| Unknown | 4 (5.5) | 3 (7) | 1 (4) | 1 (1) | 1 (2) | 0 (0) |
| MAC | 33 (45) | 18 (40) | 15 (54) | 31 (43) | 21 (42) | 10 (45) |
| Cyclophosphamide/TBI | 24 (33) | 13 (29) | 11 (39) | 22 (31) | 17 (34) | 5 (23) |
| Busulfan/cyclophosphamide | 9 (12) | 5 (11) | 4 (14) | 9 (13) | 4 (8) | 5 (23) |
| RIC | 40 (55) | 27 (60) | 13 (46) | 41 (57) | 29 (58) | 12 (55) |
| Fludarabine/melphalan | 40 (55) | 27 (60) | 13 (46) | 41 (57) | 29 (58) | 12 (55) |
| CMV status | ||||||
| D+R+ | 30 (41) | 14 (31) | 16 (57) | 25 (35) | 10 (20) | 15 (68) |
| D+R− | 10 (14) | 8 (18) | 2 (7) | 12 (17) | 9 (18) | 3 (14) |
| D−R+ | 19 (26) | 15 (33) | 4 (14) | 18 (25) | 15 (30) | 3 (14) |
| D−R− | 14 (19) | 8 (18) | 6 (21) | 17 (24) | 16 (32) | 1 (5) |
| ABO disparity | ||||||
| Matched | 50 (68) | 26 (58) | 24 (86) | 38 (53) | 23 (46) | 15 (68) |
| Minor mismatch | 10 (14) | 8 (18) | 2 (7) | 16 (22) | 14 (28) | 2 (9) |
| Major mismatch | 11 (15) | 10 (22) | 1 (4) | 11 (15) | 10 (20) | 1 (5) |
| Major and minor mismatch | 2 (3) | 1 (2) | 1 (4) | 7 (10) | 3 (6) | 4 (18) |
Unless otherwise noted, data are n (%).
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CR1, first complete remission; MDS. myelodysplastic syndrome; SD, standard deviation.